These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36672367)

  • 21. Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.
    Gkekas I; Novotny J; Pecen L; Strigård K; Palmqvist R; Gunnarsson U
    Anticancer Res; 2017 Dec; 37(12):6563-6574. PubMed ID: 29187431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer.
    Wang F; Lu S; Cao D; Qian J; Li C; Zhang R; Wang F; Wu M; Liu Y; Pan Z; Wu X; Lu Z; Ding P; Li L; Lin J; Catteau A; Galon J; Chen G
    Oncoimmunology; 2023; 12(1):2161167. PubMed ID: 36632564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status.
    Akce M; Zakka K; Jiang R; Williamson S; Alese OB; Shaib WL; Wu C; Behera M; El-Rayes BF
    Front Oncol; 2021; 11():592351. PubMed ID: 33859934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of a modified Immunoscore in patients with stage I
    Zhao K; Wu X; Li Z; Wang Y; Xu Z; Li Y; Wu L; Yao S; Huang Y; Liang C; Liu Z
    Chin J Cancer Res; 2021 Jun; 33(3):379-390. PubMed ID: 34321834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.
    Reichling C; Taieb J; Derangere V; Klopfenstein Q; Le Malicot K; Gornet JM; Becheur H; Fein F; Cojocarasu O; Kaminsky MC; Lagasse JP; Luet D; Nguyen S; Etienne PL; Gasmi M; Vanoli A; Perrier H; Puig PL; Emile JF; Lepage C; Ghiringhelli F
    Gut; 2020 Apr; 69(4):681-690. PubMed ID: 31780575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunoscore and Its Predictive Value for Colorectal Cancer].
    Závadová E; Špaček J; Vočka M; Konopásek B; Fučíková T; Netíková I; Dundr P; Skálová H; Petruželka L
    Klin Onkol; 2015; 28 Suppl 4():4S82-5. PubMed ID: 26647895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new method for predicting survival in stage I non-small cell lung cancer patients: nomogram based on macrophage immunoscore, TNM stage and lymphocyte-to-monocyte ratio.
    Gao J; Ren Y; Guo H; Mao R; Xie H; Su H; She Y; Deng J; Yang M; Han B; Zhang Y; Li J; Xie D; Chen C
    Ann Transl Med; 2020 Apr; 8(7):470. PubMed ID: 32395514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
    Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
    Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer.
    Boscolo A; Fortarezza F; Lunardi F; Comacchio G; Urso L; Frega S; Menis J; Bonanno L; Guarneri V; Rea F; Conte P; Calabrese F; Pasello G
    Front Oncol; 2020; 10():564915. PubMed ID: 33072595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology.
    Zeng L; Li SH; Xu SY; Chen K; Qin LJ; Liu XY; Wang F; Fu S; Deng L; Wang FH; Miao L; Li L; Liu N; Wang R; Wang HY
    Front Immunol; 2022; 13():878457. PubMed ID: 35619699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
    Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
    Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.
    Guo C; Zhao H; Wang Y; Bai S; Yang Z; Wei F; Ren X
    Front Oncol; 2019; 9():439. PubMed ID: 31192136
    [No Abstract]   [Full Text] [Related]  

  • 37. The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions.
    Pagès F; Taieb J; Laurent-Puig P; Galon J
    Oncoimmunology; 2020 Aug; 9(1):1812221. PubMed ID: 32939329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy.
    Li XD; Huang CW; Liu ZF; Jiang LJ; Chen JW; Xie D; Zhou FJ; Lu HM; Liu ZW
    Ann Surg Oncol; 2019 Nov; 26(12):4148-4156. PubMed ID: 31376036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
    Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
    Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.